WO2013066374A3 - Humanin protection of dopaminergic neurons - Google Patents
Humanin protection of dopaminergic neurons Download PDFInfo
- Publication number
- WO2013066374A3 WO2013066374A3 PCT/US2012/000535 US2012000535W WO2013066374A3 WO 2013066374 A3 WO2013066374 A3 WO 2013066374A3 US 2012000535 W US2012000535 W US 2012000535W WO 2013066374 A3 WO2013066374 A3 WO 2013066374A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dopaminergic neurons
- humanin
- protection
- disease
- methods
- Prior art date
Links
- 210000005064 dopaminergic neuron Anatomy 0.000 title abstract 2
- DPEUWKZJZIPZKE-OFANTOPUSA-N 330936-69-1 Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 DPEUWKZJZIPZKE-OFANTOPUSA-N 0.000 title 1
- 101000988651 Homo sapiens Humanin-like 1 Proteins 0.000 title 1
- 102000011854 humanin Human genes 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010029350 Neurotoxicity Diseases 0.000 abstract 1
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract 1
- 230000007135 neurotoxicity Effects 0.000 abstract 1
- 231100000228 neurotoxicity Toxicity 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Methods are provided for treating Parkinson's disease, protecting dopaminergic neurons from neurotoxicity and for increasing DJ-1 levels in neruons. Methods are also provided for identifying candidate treatments for Parkinson's disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161554660P | 2011-11-02 | 2011-11-02 | |
| US61/554,660 | 2011-11-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2013066374A2 WO2013066374A2 (en) | 2013-05-10 |
| WO2013066374A3 true WO2013066374A3 (en) | 2013-07-04 |
Family
ID=48192971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2012/000535 WO2013066374A2 (en) | 2011-11-02 | 2012-11-02 | Humanin protection of dopaminergic neurons |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2013066374A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024080440A1 (en) * | 2022-10-12 | 2024-04-18 | 동아대학교 산학협력단 | Composition for preventing or treating neurodegenerative disorders, comprising humanin peptide as active ingredient |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050233326A1 (en) * | 2002-06-14 | 2005-10-20 | Shuji Hinuma | Novel screening method |
| US7371225B2 (en) * | 2002-09-24 | 2008-05-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for convection enhanced delivery of therapeutic agents |
-
2012
- 2012-11-02 WO PCT/US2012/000535 patent/WO2013066374A2/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050233326A1 (en) * | 2002-06-14 | 2005-10-20 | Shuji Hinuma | Novel screening method |
| US7371225B2 (en) * | 2002-09-24 | 2008-05-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for convection enhanced delivery of therapeutic agents |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013066374A2 (en) | 2013-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011141823A3 (en) | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists | |
| PH12014500767A1 (en) | Compositions for the treatment of dry eye | |
| CA2865011C (en) | Methods and compositions for treating huntington's disease | |
| WO2016037157A3 (en) | Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies | |
| IL237369B (en) | N-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3,-tetrafluoropropoxy)benzylamine in combination with an acetylcholinesterase inhibitor for treating alzheimer's disease | |
| EP2779564A4 (en) | Method and system for authenticating user's identity and equipment used therein | |
| ZA201402049B (en) | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism | |
| WO2014058875A3 (en) | Combination therapies and uses for treatment of demyelinating disorders | |
| WO2014089241A3 (en) | Molecular profiling for cancer | |
| WO2012062925A3 (en) | Compounds and methods for treating pain | |
| TR201905683T4 (en) | Ophthalmic formulation and method for erosive presbyopia. | |
| WO2012174338A3 (en) | Method of selecting therapeutic indications | |
| HK1220980A1 (en) | Methods and compositions for treatment of pompe disease | |
| WO2010118243A3 (en) | Use of il-27 antagonists to treat lupus | |
| MX2012000034A (en) | Methods for treating or preventing fatigue. | |
| WO2012173846A3 (en) | Peptidomimetic macrocycles | |
| WO2012135365A3 (en) | Systems and methods for use in treating sensory impairment | |
| WO2012158672A3 (en) | Compounds for use in treatment of mucositis | |
| WO2012154695A3 (en) | Treatment of polycystic disease | |
| EP3558340A4 (en) | Methods of using gm6 in diagnosing and treating alzheimer's disease | |
| EP2558104A4 (en) | Method and ophthalmic composition for treating retinal disease | |
| WO2013040251A3 (en) | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease | |
| WO2014004934A3 (en) | Compositions and methods of treating alzheimer's disease | |
| WO2012170742A3 (en) | Treatment and prevention of cancer with hmgb1 antagonists | |
| HK1214517A1 (en) | 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12846677 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12846677 Country of ref document: EP Kind code of ref document: A2 |